Valproate in bipolar disorder

2000 Onwards

C. L. Bowden, V. Singh

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objective: To describe the evidence for the efficacy and tolerability of valproate in treatment of bipolar disorders, as well as factors associated with favorable or unfavorable outcomes. Method: Studies published from 2000 onwards were reviewed, as well as published abstracts. For clinical trials, randomized, prospective studies were emphasized. Results: Several mechanisms of action of valproate on central nervous system neurons that may be relevant to its actions in bipolar disorders have been recently reported. These include inhibition of glycogen synthase kinase and activation of extracellular signal-regulated kinase. Several of the actions overlap those observed from lithium. Valproate is effective in treatment of mania, and somewhat more effective in certain patient subgroups than other treatments, e.g. mixed mania, and mania with prominent irritability. Valproate is comparable with olanzapine in maintenance treatment, and somewhat better tolerated. Higher serum levels, particularly above 110 μg/ml, are associated with more reports of weight gain, sedation, and reductions in platelet count. Valproate may be associated with an increased rate of polycystic ovarian syndrome, with increased weight contributing to the risk. Valproate reduces total cholesterol levels, particularly among patients with baseline elevations of cholesterol. Several studies indicate that valproate can be beneficially combined with antipsychotic drugs and other treatments for bipolar disorder. Conclusion: Valproate continues to be studied in further clarification of its mechanisms, efficacy, risks, and spectrum of benefits in bipolar disorder. It is a major treatment for bipolar disorder, both in monotherapy and combination therapy regimens.

Original languageEnglish (US)
Pages (from-to)13-20
Number of pages8
JournalActa Psychiatrica Scandinavica, Supplement
Volume111
Issue number426
StatePublished - 2005

Fingerprint

Valproic Acid
Bipolar Disorder
olanzapine
Therapeutics
Cholesterol
Glycogen Synthase Kinases
Polycystic Ovary Syndrome
Extracellular Signal-Regulated MAP Kinases
Platelet Count
Lithium
Antipsychotic Agents
Weight Gain
Weight Loss
Central Nervous System
Randomized Controlled Trials
Prospective Studies
Neurons
Weights and Measures
Serum

Keywords

  • Bipolar disorder
  • Clinical trials
  • Mood stabilizers
  • Treatment
  • Valproate

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Valproate in bipolar disorder : 2000 Onwards. / Bowden, C. L.; Singh, V.

In: Acta Psychiatrica Scandinavica, Supplement, Vol. 111, No. 426, 2005, p. 13-20.

Research output: Contribution to journalArticle

Bowden, CL & Singh, V 2005, 'Valproate in bipolar disorder: 2000 Onwards', Acta Psychiatrica Scandinavica, Supplement, vol. 111, no. 426, pp. 13-20.
Bowden, C. L. ; Singh, V. / Valproate in bipolar disorder : 2000 Onwards. In: Acta Psychiatrica Scandinavica, Supplement. 2005 ; Vol. 111, No. 426. pp. 13-20.
@article{daaa1945f5dc4db29fd2cbf5227e180c,
title = "Valproate in bipolar disorder: 2000 Onwards",
abstract = "Objective: To describe the evidence for the efficacy and tolerability of valproate in treatment of bipolar disorders, as well as factors associated with favorable or unfavorable outcomes. Method: Studies published from 2000 onwards were reviewed, as well as published abstracts. For clinical trials, randomized, prospective studies were emphasized. Results: Several mechanisms of action of valproate on central nervous system neurons that may be relevant to its actions in bipolar disorders have been recently reported. These include inhibition of glycogen synthase kinase and activation of extracellular signal-regulated kinase. Several of the actions overlap those observed from lithium. Valproate is effective in treatment of mania, and somewhat more effective in certain patient subgroups than other treatments, e.g. mixed mania, and mania with prominent irritability. Valproate is comparable with olanzapine in maintenance treatment, and somewhat better tolerated. Higher serum levels, particularly above 110 μg/ml, are associated with more reports of weight gain, sedation, and reductions in platelet count. Valproate may be associated with an increased rate of polycystic ovarian syndrome, with increased weight contributing to the risk. Valproate reduces total cholesterol levels, particularly among patients with baseline elevations of cholesterol. Several studies indicate that valproate can be beneficially combined with antipsychotic drugs and other treatments for bipolar disorder. Conclusion: Valproate continues to be studied in further clarification of its mechanisms, efficacy, risks, and spectrum of benefits in bipolar disorder. It is a major treatment for bipolar disorder, both in monotherapy and combination therapy regimens.",
keywords = "Bipolar disorder, Clinical trials, Mood stabilizers, Treatment, Valproate",
author = "Bowden, {C. L.} and V. Singh",
year = "2005",
language = "English (US)",
volume = "111",
pages = "13--20",
journal = "Acta Psychiatrica Scandinavica, Supplement",
issn = "0065-1591",
publisher = "Wiley-Blackwell",
number = "426",

}

TY - JOUR

T1 - Valproate in bipolar disorder

T2 - 2000 Onwards

AU - Bowden, C. L.

AU - Singh, V.

PY - 2005

Y1 - 2005

N2 - Objective: To describe the evidence for the efficacy and tolerability of valproate in treatment of bipolar disorders, as well as factors associated with favorable or unfavorable outcomes. Method: Studies published from 2000 onwards were reviewed, as well as published abstracts. For clinical trials, randomized, prospective studies were emphasized. Results: Several mechanisms of action of valproate on central nervous system neurons that may be relevant to its actions in bipolar disorders have been recently reported. These include inhibition of glycogen synthase kinase and activation of extracellular signal-regulated kinase. Several of the actions overlap those observed from lithium. Valproate is effective in treatment of mania, and somewhat more effective in certain patient subgroups than other treatments, e.g. mixed mania, and mania with prominent irritability. Valproate is comparable with olanzapine in maintenance treatment, and somewhat better tolerated. Higher serum levels, particularly above 110 μg/ml, are associated with more reports of weight gain, sedation, and reductions in platelet count. Valproate may be associated with an increased rate of polycystic ovarian syndrome, with increased weight contributing to the risk. Valproate reduces total cholesterol levels, particularly among patients with baseline elevations of cholesterol. Several studies indicate that valproate can be beneficially combined with antipsychotic drugs and other treatments for bipolar disorder. Conclusion: Valproate continues to be studied in further clarification of its mechanisms, efficacy, risks, and spectrum of benefits in bipolar disorder. It is a major treatment for bipolar disorder, both in monotherapy and combination therapy regimens.

AB - Objective: To describe the evidence for the efficacy and tolerability of valproate in treatment of bipolar disorders, as well as factors associated with favorable or unfavorable outcomes. Method: Studies published from 2000 onwards were reviewed, as well as published abstracts. For clinical trials, randomized, prospective studies were emphasized. Results: Several mechanisms of action of valproate on central nervous system neurons that may be relevant to its actions in bipolar disorders have been recently reported. These include inhibition of glycogen synthase kinase and activation of extracellular signal-regulated kinase. Several of the actions overlap those observed from lithium. Valproate is effective in treatment of mania, and somewhat more effective in certain patient subgroups than other treatments, e.g. mixed mania, and mania with prominent irritability. Valproate is comparable with olanzapine in maintenance treatment, and somewhat better tolerated. Higher serum levels, particularly above 110 μg/ml, are associated with more reports of weight gain, sedation, and reductions in platelet count. Valproate may be associated with an increased rate of polycystic ovarian syndrome, with increased weight contributing to the risk. Valproate reduces total cholesterol levels, particularly among patients with baseline elevations of cholesterol. Several studies indicate that valproate can be beneficially combined with antipsychotic drugs and other treatments for bipolar disorder. Conclusion: Valproate continues to be studied in further clarification of its mechanisms, efficacy, risks, and spectrum of benefits in bipolar disorder. It is a major treatment for bipolar disorder, both in monotherapy and combination therapy regimens.

KW - Bipolar disorder

KW - Clinical trials

KW - Mood stabilizers

KW - Treatment

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=18044373043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044373043&partnerID=8YFLogxK

M3 - Article

VL - 111

SP - 13

EP - 20

JO - Acta Psychiatrica Scandinavica, Supplement

JF - Acta Psychiatrica Scandinavica, Supplement

SN - 0065-1591

IS - 426

ER -